Thermo Fisher Expands Clinical Distribution in Europe
An expanded pharma services supply chain facility in Germany boosts Thermo Fisher’s Pharma Services footprint in Europe.
Thermo Fisher Scientific announced plans to increase the company’s capacity in Europe for cold and ambient clinical trial materials by investing $35 million in a pharma services supply chain facility in Rheinfelden (Baden) Germany.
The facility will be scalable for mixed-use space and provide a “strategic logistical location” for shipping by road or air, the company reported in a March 16, 2018 press statement. Plans for the facility, which will provide up to 200 new jobs locally, were announced at a Rheinfelden council meeting.
Construction of the 8000-sq.-m expansion is scheduled to begin in the fourth quarter of 2018 with completion in 12–18 months. The investment includes the option for additional expansion that could potentially double the footprint, the company reports. The new facility will address requirements for drug supply safety including Clinical Trial Regulations Annex 6 and the Falsified Medicines Directive to be implemented in 2019.
Thermo Fisher’s Pharma Services includes Patheon’s drug development and manufacturing services and Fisher Clinical Services.
Source: Thermo Fisher Scientific
